Yumanity Therapeutics, Inc. YMTX
We take great care to ensure that the data presented and summarized in this overview for YUMANITY THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding YMTX
View allLatest Institutional Activity in YMTX
Top Purchases
Top Sells
About YMTX
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Insider Transactions at YMTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Keith Baker Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
247,933
-100.0%
|
-
|
|
Jun 30
2025
|
Shawn Iadonato |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,553
-100.0%
|
-
|
|
Jun 30
2025
|
Shawn Iadonato |
SELL
Sale (or disposition) back to the issuer
|
Direct |
860,377
-100.0%
|
-
|
|
Jun 30
2025
|
Thierry Guillaudeux Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
217,333
-100.0%
|
-
|
|
Jun 30
2025
|
Marion R Foote |
SELL
Sale (or disposition) back to the issuer
|
Direct |
165,156
-100.0%
|
-
|
|
Jun 30
2025
|
Kimberlee C Drapkin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,794
-100.0%
|
-
|
|
Jun 30
2025
|
Richard Peters |
SELL
Sale (or disposition) back to the issuer
|
Direct |
101,891
-100.0%
|
-
|
|
Jun 30
2025
|
Craig W. Philips President and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
34,654
-100.0%
|
-
|
|
Jun 30
2025
|
Craig W. Philips President and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
298,464
-100.0%
|
-
|
|
Jun 30
2025
|
Scott J. Dylla |
BUY
Sale (or disposition) back to the issuer
|
Direct |
17,794
+100.0%
|
-
|
|
Jun 30
2025
|
David Arkowitz |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,571
-100.0%
|
-
|
|
Jun 30
2025
|
Raymond J. Bartoszek |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,750,474
-100.0%
|
-
|
|
Jun 30
2025
|
Raymond J. Bartoszek |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,000
-100.0%
|
-
|
|
Jun 25
2025
|
Richard Peters |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+5.56%
|
-
|
|
Jun 25
2025
|
Kimberlee C Drapkin |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+30.31%
|
-
|
|
Jun 25
2025
|
Scott J. Dylla |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+25.22%
|
-
|
|
Jun 25
2025
|
Marion R Foote |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+3.51%
|
-
|
|
Jun 25
2025
|
Raymond J. Bartoszek |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+16.22%
|
-
|
|
Jun 25
2025
|
Thierry Guillaudeux Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,100
+9.61%
|
-
|
|
Jun 25
2025
|
Craig W. Philips President and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
60,300
+16.81%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 173K shares |
|---|---|
| Exercise of conversion of derivative security | 996K shares |
| Sale (or disposition) back to the issuer | 17.8K shares |
| Sale (or disposition) back to the issuer | 3.75M shares |
|---|---|
| Payment of exercise price or tax liability | 224K shares |